ScholarIQanswers from OpenAlex & ORCID
Jérôme Fayette
ResearcherPublications, citations & collaboration network
Jérôme Fayette is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jérôme Fayette have?
ScholarIQindexed works
Jérôme Fayette has 384 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jérôme Fayette have?
ScholarIQcitation count
Jérôme Fayette has 26,360 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jérôme Fayette?
ScholarIQh-index
Jérôme Fayette has an h-index of 50 in OpenAlex.
What is the i10-index of Jérôme Fayette?
ScholarIQi10-index
Jérôme Fayette has an i10-index of 146 in OpenAlex.
What is the ORCID of Jérôme Fayette?
ScholarIQorcid
The ORCID for Jérôme Fayette is on the source record.
What is the OpenAlex record for Jérôme Fayette?
ScholarIQopenalex
The OpenAlex for Jérôme Fayette is on the source record.
What are the most-cited papers on Jérôme Fayette?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Vijayvel Jayaprakash, Li Li, Maura L. Gillison